HilleVax
HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines.
HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines.
HilleVax is a biopharmaceutical company founded in 2021 with a focus on the development and commercialization of novel vaccines. The company's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection. HilleVax, based in the United States, recently secured a significant $100.00M Post-IPO Equity investment on 19 September 2023. This infusion of capital reflects a robust interest in the company's innovative approach to vaccine development and marks a significant milestone in its growth trajectory. The continued support from investors underscores the potential of HilleVax in shaping the future of biopharma, biotechnology, health care, and the pharmaceutical industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $100.00M | - | 19 Sep 2023 | |
| Venture Round | $135.00M | 10 |
|
08 Sep 2021 |
No recent news or press coverage available for HilleVax.
We care about your data, and we'd love to use cookies make your experience better.
